United States: AbbVie Documents Not Protected by Privilege In FTC Sham Litigation Suit

Federal Trade Commission v. AbbVie, Inc.,
(E.D. Penn. December 13, 2015)

The U.S. District Court for the Eastern District of Pennsylvania ordered AbbVie, Inc. and Besins Healthcare to produce unredacted documents to the Federal Trade Commission (FTC), because the documents were relevant to the FTC's pay-for-delay and sham litigation claims and contained business advice and analysis provided by attorneys, not legal advice. Federal Trade Commission v. AbbVie, Inc., 2015 WL 8623076, Civil Action No. 14-5151 (E.D. Penn. Dec. 13, 2015), (Bartle, J.).

The current FTC case relates to prior patent litigation involving U.S. Patent No. 6,503,894, which covered the brand-name testosterone drug, AndroGel® (testosterone gel). AndroGel was developed by Unimed Pharmaceuticals—which was later acquired by Solvay Pharmaceuticals—and Besins Healthcare. In 2009, Perrigo Company filed an abbreviated new drug application (ANDA) for a generic version of AndroGel. Solvay and Besins considered bringing a patent infringement claim, but ultimately decided against doing so. Then, in 2010, AbbVie acquired Solvay and subsequently sued both Perrigo and Teva Pharmaceutical Industries (who had also filed an ANDA) for infringement of the '894 patent. AbbVie and Teva eventually reached a settlement agreement.

In September 2014, the FTC initiated this case, alleging that AbbVie and Besins filed a sham patent litigation against Teva and Perrigo in order to delay approval of the companies' generic version of AndroGel. The FTC further alleged that the AbbVie/Teva settlement agreement was anticompetitive—claiming that Teva delayed its generic launch in return for the right to market an authorized generic version of AbbVie cholesterol drug TriCor® (fenofibrate).

After initial discovery in the case, the FTC filed a motion to compel production from both Besins and AbbVie. The FTC alleged that AbbVie and Besins improperly withheld and redacted documents. AbbVie and Besins responded by stating the documents themselves (or the redacted portions) were protected by the attorney-client privilege, the work product doctrine or both.

Besins' Challenged Documents

The first challenged document was an email from Besins' outside counsel in the United States to outside counsel in Europe, and contained a redacted sentence relaying a statement by a U.S. Patent and Trademark Office examiner during prosecution of the '894 patent. The court determined that even though the statement was from a lawyer, it simply reported a fact gathered during conversation with a third party and did not constitute legal advice and ordered production of the email.

Next, Besins redacted an email from in-house counsel in which in-house counsel reported on ongoing litigation and estimated the expected launch date of specific drugs based on that litigation. In finding the material non-privileged, the court stated that the report on ongoing litigation was for the business purpose of identifying expected launch dates, and was not providing legal advice.

Finally, Besins withheld two documents that were sent for the purpose of providing outside counsel with technical information necessary for outside counsel to provide legal advice. The court found that those documents were privileged and did not need to be produced.

AbbVie Challenged Documents

The first set of challenged AbbVie documents related to spreadsheets prepared by a non-lawyer relating to forecasting analysis for AndroGel. Because these documents were prepared at the request of counsel in order to conduct legal analysis regarding settlement discussions with Teva, the court found that the documents were protected by the work product doctrine.

Next, AbbVie withheld an email chain in which an AbbVie employee stated to another employee his desire to speak with in-house counsel. The court found that this type of communication is not between two privileged persons and is therefore not protected by privilege.

AbbVie also withheld several documents, including presentations, prepared as part of AbbVie's due diligence research in advance of its possible acquisition of Solvay. Since these documents were prepared as part of the business decision to acquire Solvay and did not relate to any pending or future litigation, the court found that the documents were not protected by attorney-client privilege or the work product doctrine.

Alternatively, the court found that communications between counsel and AbbVie and counsel for Solvay (that were exchanged after AbbVie had agreed to acquire Solvay) were protected, even though the acquisition had not been completed. The emails were protected because they related to legal advice regarding AndroGel, and because AbbVie and Solvay shared a common legal interest in AndroGel after the acquisition agreement was signed.

Finally, the court evaluated several emails between business and legal employees at Solvay relating to the '894 patent. The court found that one email included legal advice from counsel regarding patent protection was protected by attorney-client privilege. However, the remaining documents were mainly between business employees at the company and included a discussion of business strategy. Therefore, the remaining documents were not protected by attorney-client privilege or the work product doctrine.

AbbVie Documents Not Protected by Privilege in FTC Sham Litigation Suit

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.